Close Menu

NEW YORK (GenomeWeb) – NeoGenomics today reported a 25 percent year-over-year jump in its Q4 revenues, buoyed by its recently completed acquisition of Genoptix.

The cancer genetic testing company reported revenues of $76.5 million for the three-month period ended Dec. 31, 2018, up from restated revenues of $61.4 million in the same period last year. The consensus Wall Street estimate was $71.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Mar
28
Sponsored by
Qiagen

The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive collection of disease-causing, germline mutations. Since 1996, a team of experts has manually catalogued over a quarter of a million mutations for the database.  

Apr
11
Sponsored by
Bionano Genomics

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.